An Evaluation of Biotech Firms Part 2

A Comprehensive Essay

Part 2

In Part 1 of our comprehensive essay series Vertex Pharmaceuticals (VRTX) was the first firm we used to make a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. In Part 2, Vertex remains our case in point.

In Part 1 we acknowledged that we picked VRTX on March 18, 2011 at $44.39. The question is:

Why Pick Vertex in 2011?

In that year the firm had attracted the attention of those who pay attention. It was obvious that Vertex gained the respect of the scientific community in 2011. The attention of the investment community followed as Vertex demonstrated its superior capability in designing and developing new entity drugs that can defeat vicious viral infections, causing chronic devastating and life-threatening diseases.

Leave a Reply